A Phase 2/3 interventional study of cleminorexton and Placebo in Narcolepsy Type 1 and Narcolepsy Type 2, sponsored by Centessa Pharmaceuticals (UK) Limited. Recruiting at 26 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Centessa Pharmaceuticals (UK) Limited (part of Eli Lilly and Company) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Narcolepsy with a site in United States — 19 open to participants now, 20 under way, 8 of them phase 3. Narcolepsy · United States.
Among the 85 studies in Narcolepsy with a site in United States, this one is the 16th largest by planned enrollment of the 69 interventional ones that give a count, is one of 10 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 7 of the 19 other live ones, and was the 81st registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →19 of the 85 studies in Narcolepsy with a site in United States are open now. Recruiting first, the newest first:
Suven Life Sciences Limited · Sites in United States
Ages 18+
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
University of Utah · Sites in United States
Ages 18+
Takeda · Sites in United States, Australia, China and 4 more countries
Ages 18–70
Harmony Biosciences Management, Inc. · Sites in United States, Belgium, Canada and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 24 · Phase 3 24 · Phase 4 3
First in 1996; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 222 is above the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 93 across the 69 interventional studies, 191 across the 15 observational. Of the 62 that completed or were terminated, 30 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 85 have an industry lead sponsor. The 10 most frequent:
This study is registered under Centessa Pharmaceuticals (UK) Limited, one of the names counted as Eli Lilly and Company. Under that name alone:
Centessa Pharmaceuticals (UK) Limited is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Eli Lilly and Company has 2 studies filed under Narcolepsy — fewer than ten, so there is no comparison to draw.
11 of the studies in Narcolepsy with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07363720Phase 3TakedaA Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | 2026-12-17 |
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT07598708Phase 3Centessa Pharmaceuticals (UK) LimitedA Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence | 2027-09-30 |
| NCT07675135Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy | 2027-10 |
| NCT07540364Phase 3Suven Life Sciences LimitedA Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE) | 2027-11-19 |
Add all 11 to your calendar (.ics) → With an account.
Among the 85 studies in Narcolepsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.
While all conditions result in feeling sleepy, there are some differences in other common symptoms:
Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.
The SAPPHIRE Clinical Trial
The Sponsor may in the future, through a protocol amendment, expand the protocol to include participants with idiopathic hypersomnia (IH) in Cohort C.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
This study's planned enrollment of 222 is above the median of 78 across 114 interventional studies indexed under Narcolepsy.
Browse Narcolepsy studies →Centessa Pharmaceuticals (UK) Limited is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
First submitted before Centessa Pharmaceuticals (UK) Limited became part of Eli Lilly and Company.
Compared within Narcolepsy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disorders of Excessive Somnolence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: cleminorexton
Drug: cleminorexton
Drug: Placebo
Drug: cleminorexton
Drug: cleminorexton
Drug: Placebo
Oral cleminorexton capsule
matching placebo capsule
Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT)
Time frame: Baseline to week 12
Change from baseline in Epworth Sleepiness Scale (ESS) total score
Time frame: Baseline to Week 12
Weekly Cataplexy Rate (WCR)
Measurement specific to Group A
Time frame: Week 12
Change from baseline in Narcolepsy Severity Scale for Clinical Trials (NSS-CT)
Measurement specific to Group A
Time frame: Baseline to Week 12
Change from baseline in Narcolepsy Severity Scale-2 for Clinical Trials (NSS2-CT) total score
Measurement specific to Group B
Time frame: Baseline to Week 12
Incidence, Severity, and casual relationship of participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline to Week 12
Number of participants with abnormal changes from baseline in clinical laboratory tests
Time frame: Baseline to Week 12
Number of participants with abnormal changes from baseline in vital signs
Time frame: Baseline to Week 12
Number of participants with abnormal changes from baseline in 12-lead electrocardiograms (ECGs)
Time frame: Baseline to Week 12
Number of participants with at least 1 endorsement of Item 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Baseline to Week 12
Cmax: Maximum observed plasma concentration
Time frame: Baseline to Week 12
Tmax: Time of Maximum Concentration for cleminorexton
Time frame: Baseline to Week 12
AUC: Area under the plasma concentration-time curve
Time frame: Baseline to Week 12
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centessa Pharmaceuticals (UK) Limited →